Search research articles
Contact Us
Filters
Showing results (341-350 of 395) with videos related to
Page
of 40
Sort By:
JCO Global Oncology
|
May 29, 2026
Prostate Cancer Treatment Patterns and Inequities Among Racial Groups in Brazil's Public Health System: Insights From a 16-Year Real-World Study
Daniel Herchenhorn, Haonne Abboud, Vinicius Freire, et al.
European Urology
|
March 1, 2016
Change in Neutrophil-to-lymphocyte Ratio in Response to Targeted Therapy for Metastatic Renal Cell Carcinoma as a Prognosticator and Biomarker of Efficacy
Arnoud J Templeton, Jennifer J Knox, Xun Lin, et al.
The Lancet. Infectious Diseases
|
September 4, 2012
Artemisinin-resistant Plasmodium falciparum in Pursat province, western Cambodia: a parasite clearance rate study
Chanaki Amaratunga, Sokunthea Sreng, Seila Suon, et al.
Plos One
|
July 10, 2008
Phase 1 trial of malaria transmission blocking vaccine candidates Pfs25 and Pvs25 formulated with montanide ISA 51
Yimin Wu, Ruth D Ellis, Donna Shaffer, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 21, 2025
Capivasertib plus abiraterone in PTEN-deficient metastatic hormone-sensitive prostate cancer: CAPItello-281 phase III study
K Fizazi, N W Clarke, M De Santis, et al.
Malaria Journal
|
June 5, 2014
Using infective mosquitoes to challenge monkeys with Plasmodium knowlesi in malaria vaccine studies
Jittawadee R Murphy, Walter R Weiss, David Fryauff, et al.
Lancet (London, England)
|
July 19, 2025
Talazoparib plus enzalutamide in men with HRR-deficient metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trial
Karim Fizazi, Arun A Azad, Nobuaki Matsubara, et al.
BMC Medical Research Methodology
|
November 17, 2018
Development of standard clinical endpoints for use in dengue interventional trials: introduction and methodology
Thomas Jaenisch, Kim Hendrickx, Martin Erpicum, et al.
Cancer Medicine
|
February 28, 2015
HER2 as a target in invasive urothelial carcinoma
Joaquim Bellmunt, Lillian Werner, Aristotle Bamias, et al.
European Journal of Cancer (Oxford, England : 1990)
|
November 1, 2024
Talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer: Safety analyses from the randomized, placebo-controlled, phase III TALAPRO-2 study
Arun A Azad, Karim Fizazi, Nobuaki Matsubara, et al.
Page
of 40
Search research articles
Search
Showing results (341-350 of 395) with videos related to
Sort By:
Page
of 40
JCO Global Oncology
|
May 29, 2026
Prostate Cancer Treatment Patterns and Inequities Among Racial Groups in Brazil's Public Health System: Insights From a 16-Year Real-World Study
Daniel Herchenhorn, Haonne Abboud, Vinicius Freire, et al.
European Urology
|
March 1, 2016
Change in Neutrophil-to-lymphocyte Ratio in Response to Targeted Therapy for Metastatic Renal Cell Carcinoma as a Prognosticator and Biomarker of Efficacy
Arnoud J Templeton, Jennifer J Knox, Xun Lin, et al.
The Lancet. Infectious Diseases
|
September 4, 2012
Artemisinin-resistant Plasmodium falciparum in Pursat province, western Cambodia: a parasite clearance rate study
Chanaki Amaratunga, Sokunthea Sreng, Seila Suon, et al.
Plos One
|
July 10, 2008
Phase 1 trial of malaria transmission blocking vaccine candidates Pfs25 and Pvs25 formulated with montanide ISA 51
Yimin Wu, Ruth D Ellis, Donna Shaffer, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 21, 2025
Capivasertib plus abiraterone in PTEN-deficient metastatic hormone-sensitive prostate cancer: CAPItello-281 phase III study
K Fizazi, N W Clarke, M De Santis, et al.
Malaria Journal
|
June 5, 2014
Using infective mosquitoes to challenge monkeys with Plasmodium knowlesi in malaria vaccine studies
Jittawadee R Murphy, Walter R Weiss, David Fryauff, et al.
Lancet (London, England)
|
July 19, 2025
Talazoparib plus enzalutamide in men with HRR-deficient metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trial
Karim Fizazi, Arun A Azad, Nobuaki Matsubara, et al.
BMC Medical Research Methodology
|
November 17, 2018
Development of standard clinical endpoints for use in dengue interventional trials: introduction and methodology
Thomas Jaenisch, Kim Hendrickx, Martin Erpicum, et al.
Cancer Medicine
|
February 28, 2015
HER2 as a target in invasive urothelial carcinoma
Joaquim Bellmunt, Lillian Werner, Aristotle Bamias, et al.
European Journal of Cancer (Oxford, England : 1990)
|
November 1, 2024
Talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer: Safety analyses from the randomized, placebo-controlled, phase III TALAPRO-2 study
Arun A Azad, Karim Fizazi, Nobuaki Matsubara, et al.
Page
of 40